"Designing Growth Strategies is in our DNA"
Region : Global | Published Date: Upcoming | Report ID: FBI101278| Status : Pipeline
Warm autoimmune hemolytic anemia is a rare genetic disorder wherein the autoantibodies of the body prematurely self-destroy the red blood cells causing a severe case of anemia in affected patients. According to the National Organization of Rare Disorders (NORD), an estimated 3 people per 100,000 are suffering from warm autoimmune hemolytic anemia. The incidence rate of warm autoimmune hemolytic anemia is higher in adults than in children, though it can affect any kind population of irrespective of age and gender. The symptoms manifest over a period of several weeks to months depending on the progression of the disease. Common symptoms include fatigue, paleness of skin, difficulty in breathing among others.
Presently the treatment of affected individuals with warm autoimmune hemolytic anemia includes corticosteroid drugs. Immunosuppressive drugs like cyclophosphamide are also prescribed for individuals who do not respond well to corticosteroids treatment. In severe cases, surgical removal of the spleen is carried out. Rituximab is one of the most prominent monoclonal antibody drug prescribed for treatment of warm autoimmune hemolytic anemia.
Various research organization and biopharmaceutical companies are working in collaboration to discover novel therapeutics for the rare disease warm autoimmune hemolytic anemia. For instance, APL-2 a phase 2 candidate that is currently being developed by Apellis Pharmaceuticals, Inc., is studied for the safety, tolerability, and efficacy of the drug in treating warm autoimmune hemolytic anemia.
To get details on market share, speak to our analyst
Currently, an estimated 60% of the pipeline molecules for warm autoimmune hemolytic anemia are in the phase-2 clinical stage. Approximately half of the studies are funded by industry.
The report on ‘Warm Autoimmune Hemolytic Anemia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for warm autoimmune hemolytic anemia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for warm autoimmune hemolytic anemia.
The report on ‘Warm Autoimmune Hemolytic Anemia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.
Reasons to Buy this Report